Connect your AI

AngioDynamics ANGO Change in fair value of contingent consideration

Other financials

Income statement

Revenue$78.4M+8.9%

Gross profit$41.5M+6.7%

Operating income-$13.0M-29.8%

Net income-$8.1M-83.4%

EPS (diluted)-$0.19-72.7%

Balance sheet

Cash & equivalents$37.8M-15.5%

Total debt$7.9M+10.2%

Total equity$173.4M-6.7%

Total assets$260.7M-8.7%

Cash flow

Operating cash flow-$3.1M+76.4%

CapEx$1.0M-43.5%

Free cash flow-$4.1M+72.4%

Valuation

Market cap$564.42M+38.7%

Enterprise value$534.51M+48.0%

P/S1.8×+0.4×

Profitability

Gross margin54.3%-0.1pp

Operating margin-11.3%-2.9pp

Net margin-10%-2.4pp

FCF margin5.5%—

Returns & leverage

Return on equity-17.5%-2.2pp

Debt / equity0×0.0×

Current ratio2.4×+0.1×

Where this comes from

Reported directly by AngioDynamics in its filing.

Tagged under the XBRL concept ango:ChangeInFairValueOfContingentConsiderationOne.

The official record: AngioDynamics’s 10-Q, filed April 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about AngioDynamics's change in fair value of contingent consideration.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is AngioDynamics's change in fair value of contingent consideration?: AngioDynamics (ANGO) reported change in fair value of contingent consideration of $0 in Q4 2025.
How has AngioDynamics's change in fair value of contingent consideration changed year-over-year?: AngioDynamics's change in fair value of contingent consideration decreased by 100.0% year-over-year, from $40K to $0.